Skip Nav Destination
Issues
1 October 2007
-
Cover Image
Cover Image
Proapoptotic synergy between the antiestrogen, 4-hydroxytamoxifen (4-OHT) and the plant toxin, persin is mediated via an upregulation of Bim mRNA in human breast cancer cells. A combination of nontoxic concentrations of persin (2.76 μmol/L) or 4-OHT (7.5 μmol/L) leads to a significant enhancement of apoptosis compared to single agent treatment, and this is associated with the increase in Bim mRNA shown. Knock-down of Bim expression with specific siRNA abrogates this synergistic response. For details, see Roberts et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Review
Research Articles: Therapeutics, Targets, and Development
Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
Wenjuan Wu; Michael S. O'Reilly; Robert R. Langley; Rachel Z. Tsan; Cheryl H. Baker; Neby Bekele; Xi Ming Tang; Amir Onn; Isaiah J. Fidler; Roy S. Herbst
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines
David R. Emlet; Kathryn A. Brown; Deborah L. Kociban; Agnese A. Pollice; Charles A. Smith; Ben Brian L. Ong; Stanley E. Shackney
Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization–independent activation of the nuclear factor-κB/IκB kinase signal pathway
Seung Ho Lee; Seung Mo Son; Dong Ju Son; Sun Mi Kim; Tack Joong Kim; Sukgil Song; Dong Cheul Moon; Hyo Won Lee; Jae Chun Ryu; Do-Young Yoon; Jin Tae Hong
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.